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Abstract
Background: Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) share exposure to UV
light as the dominant risk factor, and these tumors therefore harbor high mutation burdens. In other malignancies,
high mutation burden has been associated with clinical benefit from therapy with antibodies directed against the
Programmed Death 1 (PD-1) immune checkpoint receptor. Highly mutated tumors are more likely to express
immunogenic tumor neoantigens that attract effector T cells, which can be unleashed by blockade of the PD-1
immune checkpoint.
Case presentations: This report describes a patient with metastatic BCC and a patient with metastatic CSCC who were
treated with REGN2810, a fully human anti-PD-1 monoclonal antibody, in an ongoing phase 1 trial (NCT02383212). The
CSCC patient has experienced an ongoing complete response (16+ months), and the BCC patient has experienced an
ongoing partial response (12+ months).
Conclusions: These case reports suggest that UV-associated skin cancers, beyond melanoma, are sensitive to
PD-1 blockade.
Trial registration: Clinicaltrials.gov NCT02383212. Registered 2 February 2015.
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Background
Basal cell carcinoma (BCC) and cutaneous squamous
cell carcinoma (CSCC) share exposure to UV light as
the dominant risk factor, and these tumors therefore
harbor high mutation burdens [1–3]. In other malignan-
cies, high mutation burden has been associated with
clinical benefit from therapy with antibodies directed
against the Programmed Death 1 (PD-1) immune check-
point receptor [4]. Highly mutated tumors are more
likely to express immunogenic tumor neoantigens that
attract effector T cells, which can be unleashed by block-
ade of the PD-1 immune checkpoint [5]. This report
describes a patient with metastatic BCC and a patient
with metastatic CSCC who were treated with
REGN2810, a fully human anti-PD-1 monoclonal anti-
body in an ongoing phase 1 trial (NCT02383212).
Case presentation 1
Basal cell carcinoma
The patient is a 66 year-old woman who was diagnosed
with a primary desmoplastic BCC arising on the left
aspect of the chin in April 2008, which was resected
with Mohs surgery. A localized recurrence in the same
location was identified in June 2010, and a wide local
excision revealed invasion into the left mandible and
involvement of one out of 18 lymph nodes. The patient
received adjuvant radiation and remained in remission
until 2014, when enlarging lung nodules observed on
surveillance chest imaging were biopsied and confirmed
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the presence of metastatic BCC. The patient subse-
quently received the Hedgehog pathway inhibitor (HHI)
vismodegib from September 2014 until February 2015.
She initially responded but discontinued because of pro-
gressive disease.
In August 2015 after continued slow progression, the
patient enrolled on the phase 1 study of REGN2810 to a
cohort receiving 10 mg/kg IV every 2 weeks, and
received her first dose on August 3, 2015. Two lung
metastases were followed as target lesions. The patient
has not experienced any treatment-related adverse
events of grade 1 or higher. Response assessments at the
end of 8 weeks (3 % increase) and 16 weeks (10 %
decrease) demonstrated stable disease by RECIST cri-
teria. The response assessment at the end of 24 weeks
demonstrated a reduction in target lesion measurements
of 37 % (Fig. 1a), and this was confirmed at 32 weeks.
Two sub-centimeter non-target lesions in the lung were
stable (not shown). The patient completed the planned
48 weeks of protocol treatment with REGN2810 on June
20, 2016, and began post-treatment follow up with her
medical oncologist. As of most recent radiology assess-
ment on August 3, 2016, partial response has been
maintained and the patient continues in post-treatment
follow-up (12+ months).
Next generation DNA sequencing (NGS) of an ar-
chived recurrent disease tumor sample was performed at
Foundation Medicine, Inc (315 gene panel, Foundatio-
nOne™). This identified 14 genetic alterations (PTCH1
Y334*, ERBB4 E317K, KIT M882I, ATR R668W, GRM3
S154F, MYCN P44F, TP53 P177L, TP53 Q100*, TP53
S215N, FGF6 E119K, GRIN2A R1067W,INHBA R306C,
PPP2R1A P179L, and TERT promoter -124C > T) that
were predicted not to be present in germline. Immuno-
histochemistry (IHC) analysis of PD-L1 expression in
this sample was negative (no staining) in tumor and
infiltrating immune cells, using the rabbit anti-human
clone SP142 (Spring Bioscience, Pleasanton, CA) and the
BenchMark XT automated system (Ventana Medical
Systems, Inc., Tucson, AZ).
Case presentation 2
Cutaneous squamous cell carcinoma
The patient is a 52 year-old man who was diagnosed
with cutaneous squamous cell carcinoma of the left
cheek in May 2002. He underwent Mohs surgery with
clear margins. He experienced multiple recurrences, and
underwent at least 9 additional Mohs surgeries. He
underwent wide local excision over left mandible in
April 2006, and left parotidectomy in February 2008.
Adjuvant RT was administered to left cheek (February -
April 2005), left mandible (May 2006), left neck (with
concurrent cetuximab, April - June 2008), and bilateral
neck (with concurrent carboplatin, April - May 2010).
Other systemic therapies were capecitabine (March -
April 2008), and cisplatin + docetaxel (February - March
2010). On November 14, 2012 he underwent excision
with clear margins for a 2.2 cm in-scar recurrence of the
left neck. On February 18, 2015, invasive CSCC at
C4-C5 vertebral bodies necessitated emergent decom-
pression of cervical spinal cord with C4-C5 anterior
corpectomy and C4-C6 posterior laminectomy.
In March 2015, he was enrolled on the phase 1 study
in the first cohort, receiving 1 mg/kg REGN2810 every 2
weeks by vein. First dose was March 30, 2015. The
patient generally tolerated treatment well, with transient
grade 1 skin rash, one day of grade two shaking chills
and grade 1 flu-like symptoms, and grade 2 lymphopenia
all deemed related to study drug. Response at Week 16
is shown in Fig. 1b. Complete radiologic response of the
A B
Fig. 1 a Lung metastases in BCC patient indicated by yellow arrows at baseline (upper, 1.6 cm; lower 1.4 cm), left, and at Week 24 (upper, 1.3 cm;
lower, 0.6 cm), right. b Neck mass in CSCC patient at baseline (3.1 cm), left, and at Week 16 (1.6 cm), right. The lesions shown are the only target
lesions for both patients
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left neck lesion was achieved at Week 40. The patient
completed the planned 48 weeks of protocol treatment
with REGN2810 on February 15, 2016. He continues on
post-treatment follow up with his medical oncologist
without clinical or radiographic evidence of disease
recurrence at the most recent radiology assessment
(16+ months) on August 8, 2016.
A formalin-fixed paraffin-embedded (FFPE) block was
prepared from the C4-C5 CSCC corpectomy specimen and
NGS (50 gene panel, Ion AmpliSeq V2) was performed at
the treating physician’s institution, along with matched
germline sequencing from blood. NGS revealed a spectrum
of somatic mutations (TP53 Q100X, FBXW7 G437E,
CTNNB1 H36Y, PIK3CA L113F, KDR S1200F) that were
present in tumor but not matched normal blood.
Discussion
We report the first confirmed partial response in a pa-
tient with metastatic BCC treated with a PD-1 inhibitor
(REGN2810), as well as an ongoing complete response
in a patient with metastatic CSCC. The deep and sus-
tained responses of these heavily pretreated patients to
anti-PD-1 monotherapy in this phase 1 study are con-
sistent with the hypothesis that high mutation burdens
in BCC and CSCC elicit antitumor cellular immunity
that could be unleashed by blockade of the PD-1/PD-L1
checkpoint pathway. Independent lines of evidence sup-
port the study of PD-1 blockade in BCC and CSCC. The
tumor microenvironment of UV-induced tumors is im-
munosuppressive, as initially described in murine models
of UV-induced tumors in the 1980s [6]. The adaptive
cellular immune system plays a critical role in surveil-
lance and eradication of CSCC and BCC, as evidenced
by the increased risks of these cancers in solid organ
transplant recipients on immunosuppressive therapy:
greater than 65-fold for CSCC and 10-fold for BCC [7].
Activation of the innate immune system can also eradi-
cate UV-associated tumors as seen with imiquimod, a
Toll-like receptor - 7 agonist that is highly active against
small superficial BCCs [8]. Imiquimod is associated with
induction of peritumoral infiltration by CD8+ T cells [9].
There are several recent case reports of dramatic re-
sponses in patients with advanced CSCCs treated with
the PD-1 inhibitors pembrolizumab or nivolumab [10–13].
A recent report also described a patient with metastatic
BCC treated for 4 cycles with pembrolizumab off label [13],
who experienced initial disease progression followed by
stabilization of lung metastases over an 11 month period,
accompanied by development of several new cutaneous
BCC lesions that were excised during this interval. This
patient did not experience an objective partial response by
RECIST, as observed in the BCC patient in our report.
NGS results were obtained from targeted exome panels
performed on archived tumor samples from both the BCC
patient (14 alterations among 315 genes) and the CSCC
patient (5 alterations among 50 genes) in Case 1 and Case
2, respectively. In consideration of the recent observation
that it may be possible to extrapolate from targeted exome
panels to estimate total mutation counts in whole exomes
[1, 14], it is likely that both cases harbor mutation burdens
that are at least moderately high. Ongoing and planned
clinical studies with REGN2810 will allow exploration of
potential associations between mutation burden, PD-L1
expression, and efficacy in BCC and CSCC.
The clinical observations in the BCC patient and the
CSCC patient in this report converge with recent clinical
observations regarding the efficacy of anti-PD-1 or anti-
PD-L1 therapy in Merkel cell carcinoma (MCC), a less
common non-melanoma skin cancer. Pembrolizumab
achieved a response rate of 56 % (14/25) in patients with
unresectable MCC who had not received prior systemic
therapy [15]. Avelumab, an anti-PD-L1 IgG1 monoclonal
antibody, yielded objective responses in 32 % (28/88) in
patients with metastatic MCC that had been treated with
at least one prior regimen [16]. Although the mechanism
of immune response in MCC requires further study, T
cells may recognize viral antigen due to the presence of
Merkel cell polyoma virus in the majority of these
tumors, or may recognize neo-antigens arising in the
context of high mutation burden due to UV damage in
MCC tumors that are not virus-associated [17].
Among the first 60 patients treated in this phase 1
study of REGN2810, one partial response was
observed among 2 MCC patients and this response is
ongoing at 13+ months. The response was seen in
non-irradiated target lesions in an MCC patient who
was treated with 3 mg/kg REGN2810 every two
weeks, plus a single course of hypofractionated radiation
therapy (6 Gy/fraction X 5 fractions) to a non-target lesion
[18]. Also among the first 60 patients, a metastatic BCC
patient enrolled to receive 3 mg/kg REGN2810 every two
weeks plus a single course of hypofractionated radiother-
apy (6 Gy X 5 fractions to a non-target lesion) plus low
dose cyclophosphamide, and this patient has stable disease
at the most recent response assessment (16+ weeks on
study). In summary, there have been 3 objective responses
among the 5 non-melanoma skin cancer patients enrolled
in the dose escalation portion of the phase 1 study [18].
Mechanisms of anti-tumor immune response may
differ among non-melanoma skin cancers. For example,
baseline intratumoral infiltration with CD8+ T cells may
be lower in untreated BCC than in CSCC [9]. In BCC,
treatment with hedgehog inhibitors has been associated
with an influx of cytotoxic T cells and activation of adap-
tive immune functions [19]. A question for further study
is whether prior treatment with a hedgehog inhibitor, as
occurred in the BCC patient in this case report, can
potentiate anti-tumor immune responses in the context
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of subsequent anti-PD-1 therapy and if the interval since
prior hedgehog inhibitor therapy is important.
Conclusions
Here we describe a radiographic complete response in a
CSCC patient and the first reported confirmed partial
response in a BCC patient treated with the anti-PD-1
monoclonal antibody REGN2810. A general principle
appears to be that UV-associated skin cancers beyond
melanoma are sensitive to PD-1 blockade. A reductionist
model would predict that UV-associated tumors with
higher load of non-synonymous mutations will be more
responsive to PD-1 blockade than those with lower
mutation load. However, numerous other variables must
be considered, including tumor clonality, the distribu-
tions and expression patterns of effector T cells and
other immune cells in the tumor microenvironment,
and T cell receptor repertoire. The accessibility of
UV-associated skin tumors for biopsy should allow clin-
ical studies of patients with these cancers to illuminate
these core concepts in immuno-oncology. An ongoing
phase 2 trial will estimate the overall response rate of
REGN2810 in patients with unresectable or metastatic
CSCC (NCT02760498), and a similar study of REGN2810
in BCC is planned for patients who have been previously
treated with hedgehog pathway inhibitors.
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